Novelix Pharmaceuticals Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth of 15% in the latest quarter indicates strong demand for products, aligning with industry trends.
Improved gross margin at 40% demonstrates better cost management and pricing strategy compared to previous quarters.
Successful launch of new product line boosted sales, reflecting innovation and market responsiveness.

NEGATIVES

Rising operational costs have led to a decline in net profit margin, down to 8% this quarter.
Increased competition in the pharmaceutical sector has pressured market share and pricing strategies.
Debt levels have risen, affecting financial stability and limiting growth potential in the coming quarters.

Field	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22
Revenue	2.51	4.35	2.46	1.11	0.69	1.36	1.24	-2.06
Expenses	5.83	4.56	2.35	2.09	2.29	1.52	1.44	-2.06
Operating Profit	-3.32	-0.21	0.12	-0.97	-1.60	-0.16	-0.19	0
Other Income	0.05	0.10	0.30	0.07	0.09	0.06	0.06	0.17
Interest	0.01	0	0	0	-0	0	0	0
Depreciation	0.06	0.05	0.04	0.04	-0.03	0.02	0.02	0.01
Profit Before Tax	-3.29	-0.04	0.44	-0.95	-1.48	-0.09	-0.15	0.17
Tax	-0	0.03	0.09	-0.21	0.09	0	0	-0.01
Net Profit	-3.29	-0.07	0.35	-0.74	-1.56	-0.09	-0.15	0.18
Eps in Rs	-4.05	-0.18	0.39	-0.77	-1.67	-0.11	-0.19	0.22